Arrowhead Pharmaceuticals (ARWR) vs BioMarin Pharmaceutical (BMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arrowhead Pharmaceuticals (ARWR) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 68.3% versus a gain of 0.9%. Over five years, ARWR leads with a -7.1% price change compared with -27.3% for BMRN. BioMarin Pharmaceutical is the larger company by market cap ($10.63 billion vs $8.58 billion), about 1.2 times the size, while Arrowhead Pharmaceuticals is growing revenue faster (+23258.2% vs +12.9%).
BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus -0.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARWR | BMRN |
|---|---|---|
| Share price | $60.74 | $54.89 |
| Market cap | $8.58B | $10.63B |
| 1-day change | -1.20% | -0.56% |
| YTD return | -7.40% | -7.12% |
| 1-year return | +68.25% | +0.91% |
| 5-year return | -7.07% | -27.26% |
| P/E ratio (TTM) | — | 148.35 |
| Forward P/E | — | 8.28 |
| EPS (TTM) | $-2.28 | $0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $829.45M | $3.22B |
| Revenue growth (YoY) | +23258.15% | +12.87% |
| Net income (latest FY) | $-1.63M | $348.90M |
| Gross margin | — | 77.73% |
| Operating margin | 11.86% | 12.71% |
| Net margin | -0.20% | 10.83% |
| 52-week high | $95.49 | $70.98 |
| 52-week low | $34.61 | $49.26 |
| Distance from 52-week high | -36.39% | -22.67% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +76.54% | +66.92% |
| Average volume | 1.90M | 2.01M |
| Shares outstanding | 141.25M | 193.57M |
| Employees | 711 | 3,221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARWR has outperformed BMRN by 67.3 percentage points over the past year.
- BioMarin Pharmaceutical is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -0.2 cents for Arrowhead Pharmaceuticals.
- Arrowhead Pharmaceuticals grew revenue faster in its latest fiscal year (+23258.15% vs +12.87%).
About Arrowhead Pharmaceuticals
ARWR stock →Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 711 employees
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
ARWR vs BMRN FAQ
Which is bigger, Arrowhead Pharmaceuticals or BioMarin Pharmaceutical?
BioMarin Pharmaceutical (BMRN) is larger, with a market capitalization of $10.63B compared with $8.58B for Arrowhead Pharmaceuticals (ARWR).
Which stock has performed better over the past year, ARWR or BMRN?
ARWR returned +68.25% over the past 12 months, compared with +0.91% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Are Arrowhead Pharmaceuticals and BioMarin Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.